NCT04629170View on ClinicalTrials.gov

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

PHASE1CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
HealthyEnteric Hyperoxaluria
Interventions
DRUG

SYNB8802

SYNB8802 is formulated as a nonsterile solution intended for oral administration

DRUG

Placebo

In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder

Trial Locations (4)

33603

Genesis Clinical Research, Tampa

37923

Knoxville Kidney Center, Knoxville

84124

PRA Health Sciences, Salt Lake City

85715

Urological Associates of Southern Arizona (open to remote participation), Tucson

Sponsors

Lead Sponsor

Synlogic
All Listed Sponsors
lead

Synlogic

INDUSTRY

NCT04629170 - Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria | Biotech Hunter | Biotech Hunter